The FDA has placed another clinical hold on a gene therapy for Duchenne muscular dystrophy developed by Solid Biosciences, pulverising its share price. The halt of the IGNITE DMD trial was prompted by ...
Stealth BioTherapeutics' filing for rare disease drug elamipretide has been turned down by the FDA, although the company says the US regulator has given it a "path forward" for the programme.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback